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Background
According to World Health Organization (WHO), there were 14 million incidences of 
cancer and 8.2 million of cancer associated deaths in 2012. In addition, the new cases 
of cancers would increase by 70% over the next 2 decades [1]. Currently, the clinically 
available cancer treatments are chemotherapy, radiotherapy, and surgical excision. How-
ever, there are several drawbacks in using these treatment modalities. In chemotherapy, 
chemotherapeutic drugs are injected into the body for the elimination of cancerous cells. 
Chemotherapy not only kills cancerous cells but it also has side effects such as lowering 
the immunity and increasing the risk of infection, inducing problems in the digestive 
system and also damaging the nervous system. Another treatment method, radiotherapy, 
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uses radiation energy to destroy the tumor. Because it is hard to target the whole tumor, 
the radiation cannot eradicate the entire tumor effectively and the organs located around 
the targeted radiation region may lose their functionality. Surgery can be successful only 
if the exact cancer location can be approached. In the other words, the surgical option is 
not available for deep-seated tumors. Furthermore, surgery may induce the risk of infec-
tion and also cause complications on surrounding organs.
Due to the drawback of currently accepted cancer treatment modalities, alternative 
or adjunctive therapies have been sought after by clinicians. One of the promising 
treatment modalities is thermotherapy where heat is used to kill the cancerous cells. 
There are 2 major types of heating used in thermotherapy, namely hyperthermia and 
thermal ablation [2]. Hyperthermia is a thermotherapy where heat is used to increase the 
whole body or part of the body temperature from a normal body temperature of 37 °C to 
the temperature range of 41–45 °C. The heating of tumor to this temperature is used to 
enhance the therapeutic effect of radiotherapy and chemotherapy. This heating has the 
potential to selectively kill cancerous cells without harming surround healthy tissue [3]. 
Thermal ablation, as suggested by the term ‘ablation’, refers to the application of a high 
temperature, above 45  °C, with the aim to produce significant tissue destruction. This 
heating will cause cell death of both tumor and surrounding tissues, hence it has to be 
applied with caution [4].
During hyperthermia, the temperature of the tumor is increased to around 42 °C for a 
duration of an hour or longer [5, 6]. This applied heat changes the biomolecular systems 
of cells [7–10] and leads to cell death due to either apoptosis or necrosis [11–13]. There 
are strong biological rationales in accepting hyperthermia as a cancer therapy method 
[14, 15]. One of the fundamental reasons for using hyperthermia as a cancer therapy 
method is the discovery that the tumor is more sensitive to heating than healthy tissues. 
It implies that if the tumor is heated to 41–45 °C, the tumor will be destroyed without 
harming surrounding healthy tissues [16–18]. The tumor sensitivity to heat is due to the 
high acidity of the cancer cells as a consequence of the high glycolytic activities inside 
cancer cells [19]. Furthermore, the heat dissipated by blood flow protects the healthy 
tissue from overheating. As the temperature increases, the thermoregulation system 
of the body will remove the excess heat by increasing the blood flow; hence the blood 
volumetric flow rate is a function of temperature. In response to temperature rise, the 
blood flow rate in healthy tissues can increase up to 20 times higher than its preheating 
rate, while the heating would only cause an increase in the tumor blood flow rate up to 
double its flow rate [20, 21].
The rate of cell death induced by heating in hyperthermia is dependent on the tem-
perature and duration of treatment [22, 23]. Overgaard and Overgaard [24] carried out 
a study on the application of heat treatment on mouse mammary carcinoma to find out 
the relation between the temperature and time and suggested that longer heat exposure 
was required where a lower temperature of treatment was used, and vice versa [24]. The 
combination of these two parameters can be used to define the minimum heating time 
required to achieve irreversible damage on a tumor at a specific temperature setting 
[25]. This combination is expressed in the form of the thermal isoeffect dose which is 
the equivalent time–temperature heating setting that can generate the same heating out-
come [26]. The isoeffect dose can be estimated using an Arrhenius plot. The Arrhenius 
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plot depicts the time–temperature relationship of cells survival phenomenon due to 
applied heat is shown in Fig. 1. Factors affecting the Arrhenius plot include the thermo-
tolerance, pH, cell phase in a cell cycle, and cell lines [27]. Generally, there is a break-
point in the Arrhenius plot at around 43 °C which could be due to the thermotolerance 
of a patient in a prolonged heating of mild hyperthermia. The rate of cell death is double 
for every degree in temperature rise beyond the breakpoint of the Arrhenius plot. This 
killing rate decreases four to six times for every drop in temperature below the break-
point [28, 29].
Commonly used methods to determine the thermal isoeffect dose is the cumulative 
equivalent minutes at 43 °C (CEM43 °C) which is a method for the conversion of heating 
duration at a specific temperature to an equivalent minute required for heating at 43 °C 
that generates the same heating outcome [30]. CEM43  °C can be used for comparing 
various hyperthermia treatment outcomes in different studies. There are variations of 
CEM43  °C such as CEM43  °C T90, and CEM43  °C T50. T90 refers to the magnitude of 
temperature reached and exceeded by 90% of the measuring point. Similarly, T50 refers 
to the magnitude of temperature reached and exceeded by 50% of the measuring point. 
Dewey [27] suggested that CEM43 °C T90 of around 25 and CEM43 °C T50 of around 400 
were suitable for the hyperthermia treatment.
Other than using hyperthermia as a single cancer treatment modality, it can also be 
combined with other therapies to form multimodality treatment [31]. The combinations 
of hyperthermia and other cancer treatments modalities are able to provide a superior 
treatment outcome. One of the combinations is the use of hyperthermia and chemo-
therapy where heat can enhance the cytotoxicity of chemotherapeutic drugs [3, 32–36]. 
Through laboratory and clinical studies, Woodhall et al. found that better regression of 
tumors occurred in the treatment using this combination [37]. Similarly, in a number 
of studies, a synergetic effect of the combined treatment was observed and caused sig-
nificant deaths of cancerous cells [38, 39]. In addition, Shingleton proposed that heating 
might increase the effectiveness of chemotherapy by increasing the local blood supply 
and oxygenation of tissues in response to body thermoregulation in removing excessive 
heat which enhanced the uptake of chemotherapeutic drugs in the tumor [40]. An in vivo 
Fig. 1 a Typical graph of survival curve of a cell line which is heated at different temperatures for various 
durations, b typical graph of Arrhenius plot with a break point at around 43 °C
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animal study using this combination of treatment was conducted by Kossatz et al. [41] 
on breast tumor bearing nude mice. The result showed a significant reduction in tumor 
growth and complete tumor regression was observed in a number of cases.
Beside the multimodality of hyperthermia together with the chemotherapy, the tumor 
can also be treated using the synergetic effect of hyperthermia and radiotherapy [42]. 
Heating increases the cells sensitivity to radiation [43, 44]. This effect occurs because 
of the increase of blood flow that drives the tissue oxygenation enrichment and the 
momentary enhancement of radio sensitivity by facilitating formations of oxygen radical 
[3, 45, 46]. The enhancement of oxygenation in a tumor has been proved in the clinical 
trial done by Brizel et al. [47]. Furthermore, in this type of multimodality, the hyperther-
mia can suppress the healing mechanism that repairs damaged cells in the tumor [48, 
49]. This damage on the repair system was further proved in the experiment done by 
Xu et al. [50] which suggested that the hyperthermia delocalized the DNA repair pro-
tein which led to an increase in the efficiency of radiotherapy. A number of preclinical 
and clinical trials on this multimodality model have been carried out [51–54]. An animal 
model test to examine the efficiency of hyperthermia in treating prostate cancer using 
96 Copenhagen rats was done by Johannsen et al. The multimodality using hyperther-
mia and radiotherapy at a low radiation dose of 20 Gy was found to be able to produce 
the same therapeutic effect as using merely a radiation dose of 60 Gy [51]. Another ani-
mal model was done to prove the efficiency of applying hyperthermia for treatment of 
malignant glioma. The results showed a positive antitumor effect of hyperthermia on 
malignant brain tumors. Subsequently, clinical trials were performed to combine hyper-
thermia and radiotherapy for treating patients with glioblastoma multiforme [52, 53]. 
These trials showed that the target hyperthermia temperature could be achieved and the 
thermotherapy was a safe treatment modality since the therapeutic effect of hyperther-
mia had increased the overall survival rate of patients.
Advancement of thermotherapy required the involvement of experts from various 
fields including physicians, biologists, chemists, physicists, engineers, etc. This is due 
to the multidisciplinary scope in the development of thermotherapy and the transition 
process from bench to bedside. Some major technical concerns in hyperthermia have 
to be solved, including the planning, execution, monitoring and optimization of the 
treatment. This paper focuses on the application of magnetic nanoparticle heating for 
hyperthermia, specifically on the heat generation process through Néelian and Brownian 
relaxation and the recent advancement in the modeling and simulation of hyperthermia 
through these relaxation processes.
Magnetic fluid hyperthermia
In hyperthermia, heat can be generated through different methods, such as the applica-
tion of ultrasound [55, 56], microwave radiation [57], radiofrequency heating [58, 59], 
and laser photocoagulation [60]. These heating techniques have several common draw-
backs that hinder their clinical acceptance. The waves generated by those methods cause 
unintended hotspots because there is a difficulty for the waves to focus on targeted areas. 
In addition, the waves have a low penetration ability [61, 62]. It is also hard to accurately 
raise and control the temperature of small tumors or deep-seated tumors using these 
methods [63]. Magnetic fluid hyperthermia (MFH) offers a solution to tackle the issues.
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The magnetic nanoparticles have a wide range of applications in the biomedical sector 
[5, 64–67]. The use of MFH as a cancer therapy can be traced back to 1957 in a study car-
ried out by Gilchrist et al. [68]. In their work on an animal model, MFH was concluded 
as a compelling method for the treatment of lymph nodes. At present, a number of stud-
ies have shown that the MFH alone could generate enough power to cause a complete 
regression of a tumor [69–71]. The use of MFH offers the solution to solve the hotspots 
and targeting issues that occur in other hyperthermia heating methods. The unwanted 
hot spots formation in the non-targeted area can be avoided in MFH because the use of 
nanoparticles offers a better control of energy deposition in the tumors by heating only 
the vicinity of particles [72]. For targeting issues, the high surface to volume ratio of mag-
netic nanoparticles enables the functionalization of particle surface with cancer-targeting 
molecules where a lot of researches are still ongoing to identify the suitable coating mate-
rials [73]. In addition, the targeting process can also be guided by the magnetic parti-
cle imaging [74, 75]. Besides, MFH offers other benefits, as hyperthermia is a minimally 
invasive treatment and the applied heat can be controlled therefore it minimizes the side 
effects. Besides, it can be used to treat complex geometries tumors. It can be used for 
treating the tumors hidden in vital organs where a surgical excision is not feasible [61]. 
The MFH has been assessed in a number of pre-clinical and clinical trials. An animal 
model was designed by Johannsen et al. to test the prospect of MFH in treating prostate 
cancer [76]. In their study, 48 male Copenhagen rats were treated with hyperthermia with 
a magnetic field frequency of 100 kHz and a field strength of 0–18 kA m−1. The results 
showed a significant difference in the tumor weight between the treated and control 
group. A follow-up prospective clinical trial on humans was conducted where 10 patients 
with locally recurrent prostate cancers underwent 6 thermal therapies [77]. In this study, 
the applied heat was found to be tolerable by the patients and the heating method using 
nanoparticles was successful. Besides, for the treatment prostate cancer, the use of MFH 
has been tested in for the treatment of different types of cancer on animal models. In a 
study on treating breast and pancreatic cancer using MFH, positive treatment outcome 
was obtained where a decline in the cancer cell proliferation and an increase in the apop-
tosis and necrosis were observed [78]. Another study on the rat breast carcinoma model 
showed that hyperthermia could inhibit tumor growth by downregulating the vascular 
endothelial growth factor and inhibiting the angiogenesis process in the tumor [79].
Magnetic nanoparticles can be delivered to the tumor through four different 
approaches, i.e. the arterial injection, the direct injection into the tumor region, the 
in situ implant formation using entrapped nanoparticle gel, and the active targeting by 
coating with the targeting ligands [80]. After the delivery of magnetic nanoparticles, 
an alternating magnetic field is activated to generate heat in the nanoparticles through 
an energy conversion based on the principle of the hysteresis loss or the Néelian and 
Brownian relaxation. Subsequently, heat dissipates to the surrounding tissues and causes 
the death of cancerous cells.
Heat generation model based on Néelian and Brownian relaxation
The heating in magnetic particles caused by changes of the magnetic field can occur 
via several mechanisms. The most well-known heating mechanism is by generating 
heat loss due to induced eddy currents which occur in bulk materials. Eddy currents 
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heating occur due to the induced currents which are the flows of electrons against the 
electrical resistance of the material. For nano-sized materials, the eddy current heating 
is extremely weak since magnetic nanoparticles have a rather poor electrical conductiv-
ity to produce a noticeable induction heating and the nano-sized dimension of particles 
cannot generate a substantial electrical voltage [81]. For particles having a size of micro 
or nano-scale, the heating due to the hysteresis loss is dominant. Heat is generated by 
thermal energy dissipated through the magnetic domain reversal process that occurs 
in the ferromagnetic material. Especially for nanoparticles with a particle size smaller 
than its superparamagnetic critical diameter, the hysteresis loss is presented in terms of 
the Néelian and Brownian relaxation. The Néelian relaxation refers to the heating due 
to the energy loss produced by the rotation of individual magnetic moments within the 
particles. On the other hand, the Brownian relaxation refers to the heat generated by 
the physical rotation of particles due to the alignment process of magnetic moments 
with the external applied magnetic field. In MFH, the heat dissipated by nanoparticles 
is caused by the hysteresis loss as depicts in Fig. 2. This paper focuses on the heating 
process in superparamagnetic nanoparticles and hence, the discussion is limited to the 
heat generation due to the Néelian and Brownian relaxation which is the dominated heat 
generation process in nano-sized particles. More detailed information about these dif-
ferent types of heating mechanisms can be found in refs [82–86].
The modeling of heat generation and transfer process in MFH will increase the 
understanding of MFH phenomena and allow a successful transition of this technology 
from bench to bedside. In addition, the modeling through simulation can be used in the 
planning of the treatment and it also serves as a new alternative method for temperature 
mapping due to the difficulty in the real time temperature measurement during the 
treatment [87, 88].
The superparamagnetic nanoparticles are nano-sized particles with single-
domain configuration due to the energetically instability of domain wall [89]. The 
use of these particles for hyperthermia offers benefits of allowing better dispersion 
of particles and avoiding the formation of particle aggregations. In order to qualify 
as a superparamagnetic nanoparticle, the particle’ diameter has to be smaller than its 
superparamagnetic critical diameter. These nano-sized particles exhibit a narrow 
Fig. 2 Different heat generation models in a magnetic nanoparticle in response to the alternative magnetic 
field. The short straight arrows represent the magnetic moment direction, the curved arrows represent the 
movement or change in direction, and the dash lines represent the domain boundaries in multi-domain 
particles
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hysteresis and the contributor to heat rise is the heating via Néelian and Brownian 
relaxation [90]. Rosensweig developed the formulation for the heat generation by 
superparamagnetic nanoparticles [91]. The equations for these two relaxation processes 
are given in Table 1 Eqs. 1, 2 and Table 1 Eq. 3 respectively. When Néelian and Brownian 
relaxations occur together, by using Eq. 4 Table 1 the effect of the combinatory process 
can be found. The volumetric power dissipation by monodispersed nanoparticles due 
to the applied magnetic field can be expressed as Table 1 Eqs. 5–8. These formulas are 
applicable when the susceptibility is assumed to be independent of the applied magnetic 
field. The power dissipated is often formulated in term of the specific loss power (SLP) or 
specific absorption rate (SAR), which is presented in Table 1 Eq. 9. When polydispersed 
particles are used, the heating power can be obtained by summarizing the heat generated 
from all particles as shown Table  1 Eqs.  10 and 11. Physical properties of potential 
materials used in MFH are provided in Table 2.
There are several factors affecting treatment outcome of MFH [92]. Different types 
of material offer different heating capabilities. The size of the nanoparticle’s core and 
its hydrodynamic size affect the generation and distribution of heat. The magnetic 
property of material, the anisotropy constant affects the heat generation process. 
Dynamic viscosity of the medium influences the amount of heat generated by Brownian 
motion. The variation in the applied magnetic field strength and frequency changes 
the magnitude of heat generated by superparamagnetic nanoparticles. In addition, the 
concentration of nanoparticles is proportional to the total amount of heat generated 
in the treatment. The optimization of these factors is necessary so as to acquire the 
maximum heating for the treatment [93]. However, it is important to note that the 
optimum setting in generating maximum heating outcome does not ensure if the 
Table 1 Equations used in determining the heating power
Eq. no. Parameter Equation expression Nomenclature







τ0 time constant (s)
K  anisotropy constant (J m−3)
VM magnetic volume (m3)
kB Boltzmann constant
T  absolute temperature (K)
2 Gamma, Γ Γ = KVMkBT
3 Brownian relaxation time, τB (s) τB = 3ηVHkBT η dynamic viscosity of the fluid (Pa s)
VH hydrodynamic volume (m3)






5 Volumetric power dissipation, P 
(W m−3)
P = piµ0χ0H20 f 2pi f τ1+(2pi f τ )2 µ0 free space permeability
H0 magnetic field strength (A 
m−1)
f  magnetic field frequency (s−1)
φ nanoparticles volume fraction
Md domain magnetization (A 
m−1)
6 Equilibrium susceptibility, χ0 χ0 = χi 3ξ (coth ξ − 1ξ )




8 Langevin parameter, ξ ξ = µ0MdH0VMkBT
9 Specific loss power (W kg−1) SLP = P
ρφ
ρ nanoparticle density (kg m−3)
10 Volumetric power dissipation of a 






D particle diameter (m)
lnD0 median of lnD
σ standard deviation of lnD
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condition is suitable to be used clinically as the optimization process is often analytical 
based with a number of assumptions that may deviate in real life application [94].
Type of material
The most frequently used nanoparticles in MFH is the iron oxide (maghemite or 
magnetite) because it is found tolerable by the human body and it is immuno-evasive 
[95]. An immuno-evasive behavior of particles is required for MFH to avoid unwanted 
immune response where a small amount of the nanoparticles may be taken up by 
surrounding healthy tissue. Iron oxide nanoparticles will be eaten by macrophages or 
neutral granulocytes and they will be degraded in lysosomes. The degraded form can 
be integrated into the normal iron metabolism and eliminated from the body eventually 
[96]. In addition, the iron oxide is able to generate enough power to induce MFH. Hence, 
it is an excellent biomaterial for hyperthermia [97].
Other than iron oxide nanoparticles, several alternative materials with better 
heating properties have been explored by researchers. By comparing the heating 
power of iron-cobalt and ferrite core–shell nanoparticles, it was found that iron-cobalt 
nanoparticles had a considerably higher specific loss power due to its high saturation 
magnetization [98]. The higher power dissipation reduces the required concentrations 
of nanoparticles to be injected in MFH. However, the toxicity of cobalt can be an issue 
and further processing such as coating using biomaterial is required. The comparison 
of more types of materials has been carried out where 6 types of nanoparticles, i.e. 
magnetite, maghemite, iron-cobalt, iron-platinum, barium-ferrite, and cobalt-ferrite, 
were compared [99]. It was shown that due to either the low rate of temperature change 
generated by the barium-ferrite and cobalt-ferrite or the large rate of temperature 
change produced by iron-cobalt; these materials were not recommended to be used 
Table 2 Physical properties of potential magnetic particles used in hyperthermia











Barium-ferrite 9a 300f 300–330g 5280g
380g
Cobalt-ferrite 10b 425g 180–200g 4907g
14c 120j 5290n
Iron 16d 1707d 48d 7870d
20e
Iron-cobalt 16b 1815d 1.5h 8031d
24d 1790h 15d 8140h
Iron-platinum 3b 1140i 206f 15,200h
10d 7000k
Maghemite 31b 414g 4.7l 4600g
35d 16j
Magnetite 21d 446g 23–41g 5180g
25b, c 9d
Nickel-ferrite 28c 301c −0.068c 5380n
33m
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in MFH. The study suggested that the magnetite, iron-platinum, and maghemite were 
suitable options in MFH because they would generate high enough heating power. In 
another study, it was found that iron-platinum nanoparticles have the capability to be 
the high-performance nanoheaters for their high saturation magnetization and high 
chemical stability [100]. At lower frequency, the iron-platinum nanoparticles provide 
a higher heating rate as compared to the magnetite. Since iron-platinum nanoparticles 
offer a superior heating power as compared to iron oxide nanoparticles, the amount of 
administered iron-platinum nanoparticles in generating the same quantity of heat is 
lower. In addition, the diameter of iron-platinum nanoparticles required to produce a 
higher heating rate is smaller as compared to the magnetite. This small diameter may 
increase the selectivity of nanoparticles in targeting the tumor attributable to its higher 
surface to volume ratio for functionalization on particles’ surface. Thus, the iron-
platinum nanoparticle seems to be a good alternative material used for hyperthermia. 
More studies have to be done to test the nanotoxicity of these alternative materials 
before it can be deemed as a safe material to be injected into the human body.
Particle size
The particle size influences SLP outcome significantly [97, 101–103]. Numerous studies 
tried to determine the optimum size of nanoparticles that would generate an optimum 
heating outcome. However, different studies always came out with different conclusions. 
For instance, for the size of magnetite, different optimum diameters had been proposed, 
such as 10  nm [104], 11.2  nm [105], 12  nm [106], 16  nm [103], and 19  nm [107]. 
Differences in the finding of optimum particle size used for the treatment are due to the 
differences of heating process setting; the magnetic field strength and frequency. Even 
the comparison was done by using intrinsic loss power (ILP), the results obtain will also 
be different across different studies, because of variation in the other parameters such as 
the anisotropy [86]. In order to get the real maximum heating, the particle size together 
with all other factors has to be optimized.
Anisotropy
The magnetic anisotropy influences the hyperthermia treatment outcome [83, 108]. 
Through modeling, it was revealed that the nanoparticle size at which the particle 
generated maximum heating power decreased as the anisotropy constant increased [98]. 
The approximation of optimum anisotropy used to generate optimum heating can be 
calculated analytically using proposed formulation by Carrey et al. [86]. This anisotropy 
constant can be altered through modifying the methods for synthesizing nanoparticles. 
The shapes of nanoparticles also affected the magnetic anisotropy. Coating the 
nanoparticles in order to gain additional functions may also change the anisotropy 
constant of the particles [109].
Viscosity
Types of medium also affect the treatment outcome. Using the same concentration of 
material and the same magnetic field conditions, the temperature was observed to rise 
highest in the water, followed by glycerol and the temperature rose lowest in collagen 
[110]. This phenomenon occurred because of the high viscosity of collagen that reduced 
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the Brownian relaxation effect. Another similar experimental study was done and 
concluded that the heating ability of nanoparticles was reduced with an increment in 
viscosity as a result of the reduction in the heating contribution from the Brownian 
relaxation [111]. Thus, it was anticipated that due to the high viscosity of the extracellular 
matrix in a biological tissue, the heat loss by Brownian relaxation is negligible. This 
inhibition of Brownian relaxation was further proved in the experiment carried out 
in vitro on living cells [112]. In their study, a range of different nanoparticle types was 
inserted into the cell cultures. Despite different morphologies and characteristics of 
nanoparticles, all samples showed a decline in the heating power when the nanoparticles 
were attached to the cell membrane. When the particles were inside the cells, the SLP 
dropped by half or even to its one-tenth.
Magnetic field strength
Magnetic field strength affects the temperature rise significantly [113]. The range of 
commonly used magnetic field for MFH is between 0 and 15  kA  m−1 [64, 114]. The 
increment in magnetic field strength would raise the temperature of a tumor and 
reduce the treatment duration [115]. This relationship between magnetic field strength 
and generated heat was explored in a number of experiment and simulation works and 
through those studies, it was found SAR varies linearly with the square of magnetic field 
strength [107, 116].
Magnetic field frequency
Typical magnetic field frequency used in MFH is between 0.05 and 1.2 MHz [64, 114]. It 
has been found that frequency and SAR have a linear relationship [107, 116]. It may be 
beneficial to apply a high magnetic field strength and frequency in order to produce a 
large amount of heat, but using high magnetic frequency and field strength on the human 
body may cause side effects and hence, there is a threshold that should not be exceeded. 
Based on an experimental study, the tolerable limit of applying the magnetic field on the 
human body was up to the magnetic field intensity of 35.8 A turns m−1 at a frequency of 
13.56 MHz [117]. It was recommended that the product of magnetic field strength and 
frequency used in the clinical setting should not go beyond 4.85 × 108 A turns m−1 s−1. 
However, this limit might be too stringent and a higher threshold can possibly be 
accepted [118]. More studies have to be done to clarify the maximum allowable magnetic 
field strength and frequency at different parts of the human body.
Concentration
The total amount of heat generated in MFH and the toxicity effect on cancer cells 
strongly depend on the concentration of nanoparticles [119]. As the concentration of 
nanoparticles increases, the temperature reached by a tumor increases [113, 120]. In 
the experiment using the collagen to represent the tissue behavior, it was found that by 
doubling the concentration of particles, the temperature rise was also doubled [110]. The 
increment in concentration heightens the temperature by increasing the amount of heat 
source but it does not influence SAR generated by each nanoparticle [116].
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Polydispersity
Synthesizing monodisperse particles is extremely challenging and thus for real life 
application, the polydispersity of particle diameters has to be taken into consideration in 
calculating optimized heat generation. Studies have been conducted to observe the effect 
of polydispersity on the heat generation by magnetic nanoparticles. By incorporated 
polydispersity into heat generation equations, as shown in Table 1 Eqs. 10 and 11, it was 
found that the large size distribution of particles reduced the heat production of the 
system [91]. Experimental data have shown similar finding where the heating rate was 
dependent on the polydispersity and by having a lower polydispersity of nanoparticles, 
the heating outcome generated was substantially higher [105, 121]. A proposed method 
to reduce the detrimental effect of size distribution is to have an optimum anisotropy 
which could increase the heating power [86].
Bioheat transfer model for heat distribution
In the nanoscale world, certain well-known Physics of phenomena behave differently. 
For heat transfer phenomenon, the conventional heat transfer model by conduction 
is no longer valid when the mean free path of material is below a threshold value and 
the ballistic energy transfer is more appropriate. This threshold is the mean free path 
of material. Rabin showed that the conventional heat transfer as defined by the Fourier 
law is applicable for nanoparticles with the size larger than 0.3 nm [122]. So for the heat 
distribution analysis in biological tissue during MFH, the Fourier law is applicable. It is 
important to note that there is a minimum size of the domain occupied by nanoparticles 
needed to achieve the hyperthermic temperature. Rabin proposed that a minimal region 
with a diameter of 1.1  mm occupied by nanoparticles was required to increase the 
temperature of tissue by 6 °C for hyperthermia [122].
In describing the heat transfer phenomenon, it is crucial to remember that the blood 
flow plays a significant role for dissipating heat away from tissue with the purpose of 
maintaining the homeostasis of the body [123]. When heat is applied to the biological 
tissue, there is a maximum temperature a tissue can achieve due to heat loss by the 
blood flow. Without the blood flow, the temperature of tissue will increase linearly with 
the heating time at a specific heating rate. In the presence of blood flow, the increase 
of temperature is nonlinear due to the heat loss and its rate of temperature rise is 
decreasing until it reaches the steady state. Therefore, the bioheat transfer model is 
established to take into account the heat loss term due to the blood flow for describing 
heat transfer in biological tissue [124–126].
The development of bioheat transfer equation can be traced back to more than 
60  years ago when it was first proposed by Pennes [127]. Pennes modeled the heat 
transfer in a resting human forearm by presenting extra terms to represent the heat 
generation due to the metabolism in tissue and the heat transfer between the blood 
and adjacent tissues as shown in Table 3 Eqs. 12–14. Due to the assumption made by 
Pennes, the equation developed has ignored or simplified certain features of the system 
and consequently, the solution may have only limited real life application. Pennes 
equation failed to account the directional convective phenomena and the heat exchange 
between closely packed countercurrent blood vessels. Hence, various modified models 
have been developed to overcome these weaknesses. Wulff modified the basic bioheat 
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transfer equation by introducing the effect of flow direction [128]. Chen and Holmes 
classified the blood vessels into the large vessels and the small vessels and accounted 
their effect on heat transfer separately with modified form of Pennes bioheat transfer 
equation as expressed in Table 3 Eqs. 15, 16 [129]. Taking into account the interaction 
of blood vessels, Weinbaum, Jiji and Lemons modified the model by adding the response 
of countercurrent heat exchange of artery and vein as presented in Table 3 Eqs. 17–19 
[130–132]. A more detailed review of these modified bioheat transfer model can be 
found in Ref [133].
Analytical modeling
With the aim of obtaining the temperature distribution of the hyperthermia process in 
the biological system, the heat transfer phenomenon is modeled using the bioheat heat 
transfer equation. Several attempts in deriving analytical solutions of hyperthermia 
Table 3 Equations used in describing bioheat transfer phenomena based on basic Pennes 
model [133]
Eq. no. Parameter Equation expression Nomenclature
Pennes model (1948)













+ qm + qb ρ density of medium (kg m
−3)
c medium specific heat (J kg−1 
K−1)
13 Heat transfer from 
blood to tissue, qb   
(J m−3 s−1)
qb = (ρc)bω(Ta − T ) T  tissue temperature (K)
k tissue specific thermal 




ω = ω0(1+ γ T ) qm heat production rate of tissue 
(J m−3 s−1)
qb heat transfer rate from blood to 
tissue (J m−3 s−1)
r , ∅, Z cylindrical coordinate
ω blood perfusion (s−1)
ρb blood density (kg m
−3)
cb blood specific heat (J kg
−1 K−1)
Ta arterial blood temperature (K)
ω0 baseline of volumetric flow 
rate of blood (s−1)
γ time dependent blood flow 
coefficient (K−1)
Chen and Holmes model (1980)
15 Thermal equilibrium 
length, le (m)
le = A(ρc)bV¯U·P A flow area (m
2)
V¯  local blood velocity (m s−1)
U overall heat transfer coefficient 
(W m−2 K−1)
P circumference (m)
u¯ net volume flux (m s−1)
kp heat transfer coefficient of 
contributing vessel(W m−2 K−1)
∗ properties of large blood vessel




= ∇ · k∇T + (ρc)bω∗
(
T ∗a − T
)
− (ρc)bu¯∇T +∇ · kp∇T + qm





b V¯ · dTads = −qa rb blood vessel radius (m)
qa heat loss rate at artery wall 
(J m−1 s−1)
qv heat gain rate at vein wall 
(J m−1 s−1)
g blood bleed off rate (m s−1)
Tv venous blood temperature (K)
n vessel number density (m−2)





b V¯ · dTvds = −qv




= ∇ · k∇T + 2npi rb(ρc)bg(Ta − Tv)
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phenomena have been carried out. Analytical solutions were commonly obtained by 
simplifying problems so that exact solutions can be obtained.
Andrӓ et al. derived equations to describe the temperature distribution of MFH with 
the assumption that the nanoparticles samples were in the form of a sphere shape 
located inside the tumor [134]. Several boundary conditions were applied: firstly, the 
center of sphere had to be finite at all time; next, the temperature at the radius of infinity 
was equal to the initial temperature at all time; thirdly, the temperature distribution was 
assumed to be continuous at the interface between the tumor and the surrounding tissue 
at all time; and lastly, the heat flux was assumed to be continuous across the interfaces. 
Based on these boundary conditions, an analytical solution was derived to describe the 
temperature variation with respect to time and space. The authors further compared 
the derived solution with the experimental data and found an agreement between them. 
This analytical solution was further verified by Sawyer et  al. who carried out a study 
on the heat distribution and found an agreement between their experimental data and 
Andrӓ et al’s solution [135]. However, it is important to note that the solutions of heat 
transfer equations derived did not consider the effect of heat loss caused by the blood 
flow which might affect the heat transfer process significantly in highly perfused tissues.
An improved analytical solution took into account heat loss due to the blood flow 
in MFH was carried out by Bagaria and Johnson [136]. In their work, the developed 
model consisted of 2 spherical regions where the inner region represented the tumor 
with nanoparticles embedded in it and an outer spherical region represented the 
healthy surrounding tissues. The Pennes’ bioheat transfer was applied to the model 
with boundary conditions including a finite temperature in the tumor, continuous 
temperature and heat flow between the interface of 2 spheres, the temperature of the 
outer sphere was equal to the body temperature and the initial temperature throughout 
both regions were equal to the initial body temperature. Analytical solutions were 
derived using separation of variables method with assumptions that the heat generation 
had a quadratic spatial variation and higher order polynomials deemed to be impractical 
to be used.
Numerical modeling
Because of numerous assumptions used in deriving the analytical solution, the results 
may have oversimplified the real phenomena and have questionable accuracy. The 
complex properties of biological tissues, the human body regulation and the interaction 
between the biological environment and foreign particles are too complex to be solved 
analytically. Numerical methods in the modeling of the heat transfer phenomena can 
be useful methods to solve this complex problem. Most of the simulations of MFH heat 
transfer were carried out by using either the finite element method (FEM) or the finite 
difference method (FDM).
Sawyer et al. [135] applied FEM to model the heat transfer process in hyperthermia 
by using difference approximation method of the differential heat equation. The model 
described the heat distribution using iron-cobalt as magnetic nanoparticles in MFH for 
the fat and muscle tissues. The results showed the proposed model fitted with derived 
analytical solutions by Andrӓ et al. [134] well. Pearce et al. [137] carried out the simula-
tion using FEM to model the heat transfer from nanoparticles to surrounding biological 
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tissue in order to investigate the required power density to be generated by nanopar-
ticles in hyperthermia. They showed that the tendency of particles to cluster together 
in vivo reduced the required power density. Pavel and Stancu applied FEM in simulating 
heat transfer in MFH and demonstrated that the achievable temperature in the tumor 
decreased considerably in the presence of blood vessel near the tumor [138]. They also 
showed that a smaller dose is required to reach the hyperthermic temperature in a larger 
tumor as compared to a smaller size tumor. The heat transfer due to the different injec-
tion sites in multiple tumor regions was simulated by Pavel and Stancu in another study 
[139]. By modeling the biological system using FEM software, they showed that the 
treatment outcomes were varied for according to the tumor types and sizes of blood ves-
sels that presented near to the tumor. This study suggested the required concentration 
of nanoparticles in the hyperthermia based on the diameter of metastases in order to 
generate the optimum heating power. To further explore the effect of the blood vessel 
on heat distribution in MFH, Yue et al. [140] carried out a study using FEM to find out 
the influence of the vessel bifurcation on heat transfer in MFH. The study found that 
a larger blood bifurcation caused higher heat loss to the blood and hence, it exerted a 
higher cooling effect on temperature distribution. This study confirmed that the MFH 
treatment planning should take into account the shape, position, and size of the vessel 
bifurcation. Nabil et al. [141] showed the effect of blood flow and capillary on the dis-
tribution of nanoparticles and the temperature distribution generated. Miaskowski and 
Sawicki implemented FEM to mimic a more realistic heat transfer in the biological tissue 
by taking into consideration effects of metabolic heat, blood perfusion, and convection 
skin cooling [126]. Their study simulated the hyperthermia in breast cancer and showed 
that the proposed model could potentially be used to provide an accurate temperature 
mapping of MFH.
Another well-known numerical method commonly used in the biomedical simulation 
is FDM. Chen et  al. believed that FDM was an effective method to be used in the 
modeling of MFH heat transfer phenomena for solving the three-dimensional non-
homogenous problem in hyperthermia [142]. Rast and Harrison simulated the heat 
transfer of MFH using FDM [114]. In the model, they coupled the heat production 
using the Maxwell’s equation with the Pennes’ bioheat transfer equation. The domain 
created was a multilayer domain with the innermost layer consisted of the tumor 
and nanoparticles, covered by the gray matter which was further enclosed by the 
perfused dermal and skeletal layers. The nanoparticles were assumed to be distributed 
homogeneously all over the tumor. The results showed that blood perfusion rate 
affected the temperature rise in the tumor. Another FDM simulation was carried out by 
Bagaria and Johnson [136]. In this work, the numerical model was developed based on 
finite differencing scheme and it showed a good agreement with the derived analytical 
solution. Craciun and Calugaru also explored the use of FDM in describing the heat 
transfer in MFH [143]. They created the algorithm for solving the heat transfer equation 
by incorporating the tissue metabolism heat term and the heat sink due to the blood 
vessel. To improve the performance of the model, new technology or system can be 
introduced into the numerical modeling, such as the use of the parallel computing to 
enhance the processing speed [144].
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Optimization model
Optimization of hyperthermia process is crucial in the clinical setting for the purpose 
of maximizing the therapeutic effects and minimizing any side effects. Besides, 
optimization of MFH should ensure that the required amount of nanoparticles is as 
small as possible while the nanoparticles are still able to produce high enough heating 
power. Hence, by carrying out optimization, the limit of targeted area can be controlled, 
the potential overheating may be avoided and any harm to the surrounding healthy 
tissue may be minimized.
The optimization of MFH heating process can be found in the study done by Bagaria 
and Johnson [136]. In this study, first, the domain was modeled as 2 concentric spheres 
to represent the tumor and adjacent tissue and the Pennes’ bioheat transfer equation was 
applied. The optimization was done with objectives to sustain the therapeutic tempera-
ture in tumors and keep adjacent healthy tissue at an acceptable temperature range as 
shown in Table 4 Eq. 20. A penalty function was applied in the optimization which mini-
mized both the insufficient heating of tumor and the overheating in the normal tissue. 
Using this model setting, the authors concluded that for a fixed amount of nanoparticles, 
optimization of particle distribution in the tumor can improve the therapeutic effect on 
Table 4 Summary of optimization model for MFH
Eq. no. Parameter Equation expression Nomenclature
Bagaria and Johnson optimization 
model, 2005 [136]
20 Objective function, f
Error function for insufficient and 
overheating in tumor, E1
Error function for overheating in 
healthy tissue, E2
f = √E1 + E2
For 42 ≤ T1∞ ≤ 45
E1 = 0




For T2∞ = 37
E2 = 0




T1∞ steady state temperature of a 
point in tumor
T2∞ steady state temperature of a 
point in healthy tissue
W1 weight factor for insufficient 
heating in tumor
W2 weight factor for overheating in 
healthy tissue
Mital and Tafreshi optimization 
model, 2012 [145]
21 Objective function, f
Thermal damage, D
f =∝1 D1− ∝2 D2
D(x , y) =
tf∫
0
R(43−T (x ,y ,t))dt
∝1 weight factor for tumor damage
∝2 weight factor for healthy tissue 
damage
D1 thermal damage value of tumor
D2 thermal damage value of healthy 
tissue
tf  period of time
R empirical constant
T  temperature at a point at a time
t  time
Salloum, Ma and Zhu optimization 
model, 2009 [146]
22 Objective function, f
Error function for deviation of 
tumor boundary temperature, E
Percentage of tumor volume with 
T ≥ Tn, R1
Percentage of tumor boundary 






R1 = Vtumor,T≥TnVtumor,total · 100
R2 = Sboundary,T≥TnSboundary,total · 100
Tb temperature at tumor boundary
Tn cutoff temperature where the 
value above it is desired for tumor 
and below it for healthy tissue
Ta arterial blood temperature
V  volume
S surface area
Page 16 of 22Suriyanto et al. BioMed Eng OnLine  (2017) 16:36 
tumor and maintain the safety heating limit in the surrounding healthy tissue. A simi-
lar model setting was imposed in the study done by Mital and Tafreshi [145]. However, 
there was a slight difference in the optimization function used. Instead of just focusing 
on minimizing the error, the optimization function rewarded the therapeutic effect on 
a tumor. In the other words, it was favorable for the tumor to be heated to the range 
of therapeutic temperature while minimizing the harmful effect on surrounding tissue. 
The optimization was set by maximizing a fitness function expressed in Table 4 Eq. 21 
which value increased if there was a higher damage in the tumor and decreased if the 
treatment caused more harm to adjacent healthy tissue. Based on the available power 
dissipation records, the results of this optimization suggested the optimum treatment 
time of hyperthermia was 1 h. Another optimization of MFH heating process was done 
by Salloum et al. [146]. Salloum et al. simulated the heat transfer pattern using FEM in 
order to obtain optimum parameters for hyperthermia with multiple nanoparticle injec-
tion sites. The tumor was designed as an irregular tissue in a large cubical domain. The 
objective function was set to ensure that at least 90% of the tumor had a temperature 
rise to 43 °C while less than 10% of the surrounding healthy tissue hit the temperature of 
43 °C or higher as shown in Table 4 Eq. 22.
In order to receive clinical acceptance, the results obtained from simulation (analytical, 
numerical and optimization model) must be verified with real clinical data. However, 
a major hindrance in the verification of these methods is an unavailability of accurate 
clinical data. The temperature distribution measurement comes with errors especially 
for temperature measurement of a deep-seated tumor. The significance difference in 
thermal conductivity of metal thermocouple and surrounding biological tissue causes 
distortion in temperature measurement [147]. This thermal conductivity differences 
issue can be overcome by applying insulation on the probe. However, the use of 
insulation will also cause an error in the reading due to temperature drop across the 
sheath wall [148]. Besides, the use of a magnetic field for heating nanoparticles may also 
heat up the metal thermocouples through eddy currents heating and show an unusual 
reading. With the aim of minimizing the error in temperature measurement, careful 
thermocouple probe, and instrumentation design by taking into account the use of 
magnetic field as nanoparticle heating method is required. Exploring new alternative 
temperature mapping technique may also offer a solution for obtaining higher accuracy 
clinical temperature reading, such as the use of magnetic resonance imaging for 
temperature mapping during hyperthermia treatment [149].
Conclusion
Hyperthermia has the potential to be a new alternative therapy modality for cancer 
treatment. Hyperthermia selectively targets the tumor without harming surrounding 
tissue as the tumor has higher sensitivity to heat. A promising heating method for the 
hyperthermia therapy is MFH. Several simulations of heat transfer phenomena in MFH 
have been carried out and proposed based on the bioheat transfer equation. However, 
there are still needs for the further study of simulation that can mimic the biological 
response to the applied heat. By having a more accurate simulation, the effect of various 
parameters on the treatment outcome can be determined. In addition, it will allow 
a better control of therapy and can be used as an alternative temperature mapping 
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technique. Further optimization studies also have to be carried out to find the optimum 
material used which could generate the highest heating and the optimum treatment 
setting that can enhance the treatment outcome.
Abbreviations
FDM: finite difference method; FEM: finite element method; ILP: intrinsic loss power; MFH: magnetic fluid hyperthermia; 
SAR: specific absorption rate; SLP: specific loss power.
Authors’ contributions
S was in charge for the whole paper and contributed in all its section. EYKN contributed in the sections reviewing 
heat generation and bio-heat transfer model. SDK contributed in the section of biological rationales behind the use of 
hyperthermia. All authors read and approved the final manuscript.
Author details
1 Nanyang Institute of Technology in Health and Medicine, Interdisciplinary Graduate School, Nanyang Technological 
University, Research Techno Plaza, #02-07, 50 Nanyang Drive, Singapore 637553, Singapore. 2 Lee Kong Chian School 
of Medicine, Nanyang Technological University, Experimental Medicine Building, Level 3, Yunnan Garden Campus, 
59 Nanyang Drive, Singapore 636921, Singapore. 3 School of Mechanical and Aerospace Engineering, College 
of Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore. 
Acknowledgements
The first author (Suriyanto) acknowledges receipt of the Research Scholarship from Nanyang Institute of Technology in 
Health and Medicine, Interdisciplinary Graduate School, Nanyang Technological University, Singapore.
Competing interests
The authors declare that they have no competing interests.
Availability of data and supporting materials
No data or other supporting materials exist relevant to this work that could be made publicly available.
Funding
This work was not financially supported.
Received: 18 October 2016   Accepted: 14 March 2017
References
 1. Steward BW, Wild CP. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014.
 2. Habash RWY, Bansal R, Krewski D, Alhafid HT. Thermal therapy, part 1: an introduction to thermal therapy. Crit Rev 
Biomed Eng. 2006;34(6):459–89.
 3. Habash RWY, Bansal R, Krewski D, Alhafid HT. Thermal therapy, part 2: hyperthermia techniques. Crit Rev Biomed 
Eng. 2006;34(6):491–542.
 4. Habash RWY, Bansal R, Krewski D, Alhafid HT. Thermal therapy, part III: ablation techniques. Crit Rev Biomed Eng. 
2007;35(1–2):37–121.
 5. Barry SE. Challenges in the development of magnetic particles for therapeutic applications. Int J Hyperth. 
2008;24(6):451–66.
 6. Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperth. 
2005;21(8):779–90.
 7. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of 
hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33–56.
 8. Milleron RS, Bratton SB. ‘Heated’debates in apoptosis. Cell Mol Life Sci. 2007;64(18):2329–33.
 9. Roti Roti JL. Cellular responses to hyperthermia (40-46 C): cell killing and molecular events. Int J Hyperth. 
2008;24(1):3–15.
 10. Lepock JR. Cellular effects of hyperthermia: relevance to the minimum dose for thermal damage. Int J Hyperth. 
2003;19(3):252–66.
 11. Sellins KS, Cohen JJ. Hyperthermia induces apoptosis in thymocytes. Radiat Res. 1991;126(1):88–95.
 12. Fairbairn JJ, Khan MW, Ward KJ, Loveridge BW, Fairbairn DW, O’Neill KL. Induction of apoptotic cell DNA fragmen-
tation in human cells after treatment with hyperthermia. Cancer Lett. 1995;89(2):183–8.
 13. Harmon BV, Corder AM, Collins RJ, Gobe GC, Allen J, Allan DJ, Kerr JFR. Cell death induced in a murine mastocy-
toma by 42–47 °C heating in vitro: evidence that the form of death changes from apoptosis to necrosis above a 
critical heat load. Int J Radiat Biol. 1990;58(5):845–58.
 14. Hall EJ, Roizin-Towle L. Biological effects of heat. Cancer Res. 1984;44(10 Supplement):4708s–13s.
 15. van der Zee J. Heating the patient: a promising approach? Ann Oncol. 2002;13(8):1173–84.
 16. Brown SL, Hunt JW, Hill RP. Differential thermal sensitivity of tumour and normal tissue microvascular response 
during hyperthermia. Int J Hyperth. 1992;8(4):501–14.
 17. Overgaard J. Effect of hyperthermia on malignant cells in vivo: a review and a hypothesis. Cancer. 
1977;39(6):2637–46.
Page 18 of 22Suriyanto et al. BioMed Eng OnLine  (2017) 16:36 
 18. Westermark N. The effect of heat upon rat-tumors. Skand Arch für Physiol. 1927;52(3):257–322.
 19. Gerweck LE. Modification of cell lethality at elevated temperatures the pH effect. Radiat Res. 1977;70(1):224–35.
 20. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res. 
1984;44(2):605–12.
 21. Song CW, Lokshina A, Rhee JG, Patten M, Levitt SH. Implication of blood flow in hyperthermic treatment of 
tumors. IEEE Trans Biomed Eng. 1984;1:9–16.
 22. Henle KJ, Dethlefsen LA. Time-temperature relationships for heat-induced killing of mammalian cells. Ann NY 
Acad Sci. 1980;335(1):234–53.
 23. Bauer KD, Henle KJ. Arrhenius analysis of heat survival curves from normal and thermotolerant CHO cells. Radiat 
Res. 1979;78(2):251–63.
 24. Overgaard K, Overgaard J. Investigations on the possibility of a thermic tumour therapy—I: short-wave treatment 
of a transplanted isologous mouse mammary carcinoma. Eur J Cancer. 1972;8(1):65–78.
 25. Dickson JA, Calderwood SK. Temperature range and selective sensitivity of tumors to hyperthermia: a critical 
review. Ann NY Acad Sci. 1980;335(1):180–205.
 26. Gerner EW. Thermal dose and time—temperature factors for biological responses to heat shock. Int J Hyperth. 
1987;3(4):319–27.
 27. Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperth. 2009;25(1):3–20.
 28. Moritz A, Henriques F. The relative importance of time and surface temperature in the causation of cutaneous 
burns. Studies of thermal injury II. Am J Path. 1947;23:659.
 29. Field SB, Morris CC. The relationship between heating time and temperature: its relevance to clinical hyperther-
mia. Radiother Oncol. 1983;1(2):179–86.
 30. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 
1984;10(6):787–800.
 31. Datta NR, Ordóñez SG, Gaipl US, Paulides MM, Crezee H, Gellermann J, Marder D, Puric E, Bodis S. Local hyperther-
mia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer 
Treat Rev. 2015;41(9):742–53.
 32. Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer. 2008;44(17):2546–54.
 33. Dahl O. Interaction of heat and drugs in vitro and in vivo. In: Seegenschmiedt MH, Fessenden P, Vernon, CC, edi-
tors. Thermoradiotherapy and thermochemotherapy. Berlin: Springer; 1995. p. 103–21.
 34. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res. 1979;39(6 Part 2):2264–8.
 35. Masunaga S, Ono K, Hori H, Kinashi Y, Suzuki M, Takagaki M, Kasai S, Nagasawa H, Uto Y. Modification of tira-
pazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect 
on quiescent tumour cells. Int J Hyperth. 1999;15(1):7–16.
 36. Orel V, Shevchenko A, Romanov A, Tselepi M, Mitrelias T, Barnes CHW, Burlaka A, Lukin S, Shchepotin I. Magnetic 
properties and antitumor effect of nanocomplexes of iron oxide and doxorubicin. Nanomed Nanotechnol Biol 
Med. 2015;11(1):47–55.
 37. Woodhall B, Pickrell KL, Georgiade NG, Mahaley MS Jr, Dukes HT. Effect of hyperthermia upon cancer chemother-
apy: application to external cancers of head and neck. Ann Surg. 1960;151(5):750–8.
 38. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-
dichlorodiammineplatinum(II) and mitomycin C. Cancer Res. 1980;40(4):1165–8.
 39. Yuwen L, Cunxin W, Congyi Z, Haixiang W, Zhiyong W, Songsheng Q. Microcalorimetric study of the metabolism 
of U-937 cells undergoing apoptosis induced by the combined treatment of hyperthermia and chemotherapy. J 
Therm Biol. 2002;27(2):129–35.
 40. Shingleton WW. Selective heating and cooling of tissue in cancer chemotherapy. Ann Surg. 1962;156(3):408–14.
 41. Kossatz S, Grandke J, Couleaud P, Latorre A, Aires A, Crosbie-Staunton K, Ludwig R, Dähring H, Ettelt V, Lazaro-
Carrillo A, et al. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles 
combining magnetic hyperthermia and anti-cancer drug delivery. Breast Cancer Res. 2015;17(1):1–17.
 42. Harima K, Harada K. Synergistic cell-killing effect of a combination of hyperthermia and heavy ion beam irradia-
tion: in expectation of a breakthrough in the treatment of refractory cancers (review). Int J Mol Med. 2002;9:11–8.
 43. Kampinga HH, Dikomey E. Hyperthermic radiosensitization: mode of action and clinical relevance. Int J Radiat Biol. 
2001;77(4):399–408.
 44. van der Zee J, González D, van Rhoon GC, van Dijk JDP, van Putten WLJ, Hart AAM. Comparison of radiotherapy 
alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multi-
centre trial. Lancet. 2000;355(9210):1119–25.
 45. Vujaskovic Z, Song CW. Physiological mechanisms underlying heat-induced radiosensitization. Int J of Hyperth. 
2004;20(2):163–74.
 46. Bicher HI, Mitagvaria N. Circulatory responses of malignant tumors during hyperthermia. Microvasc Res. 
1981;21(1):19–26.
 47. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Dodge RK, Charles HC, Samulski TV, Prosnitz LR, Dewhirst MW. 
Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res. 
1996;56(23):5347–50.
 48. Masunaga S-I, Nagata K, Suzuki M, Kashino G, Kinashi Y, Ono K. Inhibition of repair of radiation-induced dam-
age by mild temperature hyperthermia, referring to the effect on quiescent cell populations. Radiat Med. 
2007;25(8):417–25.
 49. Henle KJ, Leeper DB. The modification of radiation damage in CHO cells by hyperthermia at 40 and 45 C. Radiat 
Res. 1977;70(2):415–24.
 50. Xu M, Myerson RJ, Xia Y, Whitehead T, Moros EG, Straube WL, Roti Roti JL. The effects of 41 C hyperthermia on 
the DNA repair protein, MRE11, correlate with radiosensitization in four human tumor cell lines. Int J Hyperth. 
2007;23(4):343–51.
Page 19 of 22Suriyanto et al. BioMed Eng OnLine  (2017) 16:36 
 51. Johannsen M, Thiesen B, Gneveckow U, Taymoorian K, Waldöfner N, Scholz R, Deger S, Jung K, Loening SA, Jordan 
A. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of 
prostate cancer. Prostate. 2006;66(1):97–104.
 52. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A. Efficacy and safety of 
intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy 
on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317–24.
 53. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, Feussner A, von Deimling A, Waldoefner N, Felix 
R, Jordan A. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiother-
apy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol. 2007;81(1):53–60.
 54. Attaluri A, Kandala SK, Wabler M, Zhou H, Cornejo C, Armour M, Hedayati M, Zhang Y, DeWeese TL, Herman C, 
Ivkov R. Magnetic nanoparticle hyperthermia enhances radiation therapy: a study in mouse models of human 
prostate cancer. Int J Hyperth. 2015;31(4):359–74.
 55. Fry FJ, Johnson LK. Tumor irradiation with intense ultrasound. Ultrasound Med Biol. 1978;4(4):337–41.
 56. ter Haar G, Rivens I, Chen L, Riddler S. High intensity focused ultrasound for the treatment of rat tumours. Phys 
Med Biol. 1991;36(11):1495–501.
 57. Raymond U, Noell KT, Woodward KT, Worde BT, Fishburn RI, Miller LS. Microwave-induced local hyperthermia in 
combination with radiotherapy of human malignant tumors. Cancer. 1980;45(4):638–46.
 58. Storm FK, Harrison WH, Elliott RS, Morton DL. Normal tissue and solid tumor effects of hyperthermia in animal 
models and clinical trials. Cancer Res. 1979;39(6 Part 2):2245–51.
 59. Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol. 2003;10(4):338–47.
 60. Welch AJ, Van Gemert MJC. Optical-thermal response of laser-irradiated tissue. Berlin: Springer; 1995.
 61. Jordan A, Etheridge M, Bischof JC. Magnetic nanoparticles for cancer therapy. In: Moros EG, editors. Physics of 
thermal therapy: fundamentals and clinical applications. Boca Raton: Taylor & Francis; 2013. p. 293–318.
 62. Moroz P, Jones SK, Gray BN. Status of hyperthermia in the treatment of advanced liver cancer. J Surg Oncol. 
2001;77(4):259–69.
 63. Dewhirst MW. Thermal dosimetry. In: Seegenschmiedt MH, Fessenden P, Vernon, CC, editors. Thermoradiotherapy 
and thermochemotherapy. Berlin: Springer; 1995. p. 123–36.
 64. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D 
Appl Phys. 2003;36(13):R167.
 65. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci 
Bioeng. 2005;100(1):1–11.
 66. Mornet S, Vasseur S, Grasset F, Duguet E. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater 
Chem. 2004;14(14):2161–75.
 67. Pankhurst QA, Thanh NTK, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. 
J Phys D Appl Phys. 2009;42(22):224001.
 68. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB. Selective inductive heating of lymph nodes. 
Ann Surg. 1957;146(4):596–606.
 69. Dennis CL, Jackson AJ, Borchers JA, Hoopes PJ, Strawbridge R, Foreman AR, Van Lierop J, Grüttner C, Ivkov R. Nearly 
complete regression of tumors via collective behavior of magnetic nanoparticles in hyperthermia. Nanotechnol. 
2009;20(39):395103.
 70. Johannsen M, Gneveckow U, Thiesen B, Taymoorian K, Cho CH, Waldöfner N, Scholz R, Jordan A, Loening SA, Wust 
P. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional 
temperature distribution. Eur Urol. 2007;52(6):1653–62.
 71. Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldöfner N, Scholz R, Deger S, Wust P, Loening S, Jordan A. 
Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial tech-
nique. Int J Hyperth. 2005;21(7):637–47.
 72. Hilger I, Hergt R, Kaiser WA. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEEE Proc 
Nanobiotechnol. 2005;152(1):33–9.
 73. Creixell M, Bohorquez AC, Torres-Lugo M, Rinaldi C. EGFR-targeted magnetic nanoparticle heaters kill cancer cells 
without a perceptible temperature rise. ACS Nano. 2011;5(9):7124–9.
 74. Dhavalikar R, Rinaldi C. Theoretical predictions for spatially-focused heating of magnetic nanoparticles guided by 
magnetic particle imaging field gradients. J Magn Magn Mater. 2016;419:267–73.
 75. Bauer LM, Situ SF, Griswold MA, Samia ACS. Magnetic particle imaging tracers: state-of-the-art and future direc-
tions. J Phys Chem Lett. 2015;6(13):2509–17.
 76. Johannsen M, Thiesen B, Jordan A, Taymoorian K, Gneveckow U, Waldöfner N, Scholz R, Koch M, Lein M, Jung K, 
Loening SA. Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 
rat model. Prostate. 2005;64(3):283–92.
 77. Johannsen M, Gneveckow U, Taymoorian K, Thiesen B, Waldöfner N, Scholz R, Jung K, Jordan A, Wust P, Loening 
SA. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate 
cancer: results of a prospective phase I trial. Int J Hyperth. 2007;23(3):315–23.
 78. Kossatz S, Ludwig R, Dähring H, Ettelt V, Rimkus G, Marciello M, Salas G, Patel V, Teran FJ, Hilger I. High therapeutic 
efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the 
tumor area. Pharm Res. 2014;31(12):3274–88.
 79. Wang G, Xu D, Chai Q, Tan X, Zhang Y, Gu N, Tang J. Magnetic fluid hyperthermia inhibits the growth of breast 
carcinoma and downregulates vascular endothelial growth factor expression. Oncol Lett. 2014;7(5):1370–4.
 80. Laurent S, Dutz S, Häfeli UO, Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide 
nanoparticles. Adv Colloid Interface Sci. 2011;166(1):8–23.
 81. Dutz S, Hergt R. Magnetic particle hyperthermia—a promising tumour therapy? Nanotechnology. 
2014;25(45):452001.
 82. Hergt R, Dutz S, Müller R, Zeisberger M. Magnetic particle hyperthermia: nanoparticle magnetism and materials 
development for cancer therapy. J Phys Condens Matter. 2006;18(38):S2919.
Page 20 of 22Suriyanto et al. BioMed Eng OnLine  (2017) 16:36 
 83. Hergt R, Andrä W. Magnetic hyperthermia and thermoablation. In: Andrä W, Nowak H, editors. Magnetism in 
medicine: a handbook. 2nd ed; 2007. p. 550–70.
 84. Jordan A, Wust P, Fähling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic 
fluids: physical evaluation of their potential for hyperthermia. Int J Hyperth. 2009;25(7):499–511.
 85. Hergt R, Andra W, d’Ambly CG, Hilger I, Kaiser W, Richter U, Schmidt H-G. Physical limits of hyperthermia using 
magnetite fine particles. IEEE Trans Magn. 1998;34(5):3745–54.
 86. Carrey J, Mehdaoui B, Respaud M. Simple models for dynamic hysteresis loop calculations of magnetic single-
domain nanoparticles: application to magnetic hyperthermia optimization. J Appl Phys. 2011;109(8):083921.
 87. Neufeld E, Paulides MM, van Rhoon GC, Kuster N: Numerical modeling for simulation and treatment planning 
of thermal therapy. In: Physics of thermal therapy: fundamentals and clinical applications. Boca Rotan: Taylor & 
Francis; 2013. p. 119.
 88. Krishnan S, Diagaradjane P, Cho SH. Nanoparticle-mediated thermal therapy: evolving strategies for prostate 
cancer therapy. Int J Hyperth. 2010;26(8):775–89.
 89. Goya GF, Grazu V, Ibarra MR. Magnetic nanoparticles for cancer therapy. Curr Nanosci. 2008;4(1):1–16.
 90. Okawa K, Sekine M, Maeda M, Tada M, Abe M, Matsushita N, Nishio K, Handa H. Heating ability of magnetite 
nanobeads with various sizes for magnetic hyperthermia at 120 kHz, a noninvasive frequency. J of Appl Phys. 
2006;99(8):08H102-103.
 91. Rosensweig RE. Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater. 2002;252:370–4.
 92. Shah RR, Davis TP, Glover AL, Nikles DE, Brazel CS. Impact of magnetic field parameters and iron oxide nanoparticle 
properties on heat generation for use in magnetic hyperthermia. J Magn Magn Mater. 2015;387:96–106.
 93. Dennis CL, Ivkov R. Physics of heat generation using magnetic nanoparticles for hyperthermia. Int J Hyperth. 
2013;29(8):715–29.
 94. Andreu I, Natividad E. Accuracy of available methods for quantifying the heat power generation of nanoparticles 
for magnetic hyperthermia. Int J Hyperth. 2013;29(8):739–51.
 95. Hergt R, Hiergeist R, Hilger I, Kaiser WA, Lapatnikov Y, Margel S, Richter U. Maghemite nanoparticles with very high 
AC-losses for application in RF-magnetic hyperthermia. J Magn Magn Mater. 2004;270(3):345–57.
 96. Banerjee R, Katsenovich Y, Lagos L, McIintosh M, Zhang X, Li CZ. Nanomedicine: magnetic nanoparticles and their 
biomedical applications. Curr Med Chem. 2010;17(27):3120–41.
 97. Wang X, Gu H, Yang Z. The heating effect of magnetic fluids in an alternating magnetic field. J Magn Magn Mater. 
2005;293(1):334–40.
 98. Habib AH, Ondeck CL, Chaudhary P, Bockstaller MR, McHenry ME. Evaluation of iron-cobalt/ferrite core-shell nano-
particles for cancer thermotherapy. J Appl Phys. 2008;103(7):07A307-301–307A307-303.
 99. Kappiyoor R, Liangruksa M, Ganguly R, Puri IK. The effects of magnetic nanoparticle properties on magnetic fluid 
hyperthermia. J Appl Phys. 2010;108(9):094702.
 100. Maenosono S, Saita S. Theoretical assessment of FePt nanoparticles as heating elements for magnetic hyperther-
mia. IEEE Trans Magn. 2006;42(6):1638–42.
 101. Ma M, Wu Y, Zhou J, Sun Y, Zhang Y, Gu N. Size dependence of specific power absorption of Fe3O4 particles in AC 
magnetic field. J Magn Magn Mater. 2004;268(1):33–9.
 102. Murase K, Oonoki J, Takata H, Song R, Angraini A, Ausanai P, Matsushita T. Simulation and experimental stud-
ies on magnetic hyperthermia with use of superparamagnetic iron oxide nanoparticles. Radiol Phys Technol. 
2011;4(2):194–202.
 103. Khandhar AP, Ferguson RM, Simon JA, Krishnan KM. Enhancing cancer therapeutics using size-optimized mag-
netic fluid hyperthermia. J Appl Phys. 2012;111(7):07B306.
 104. Bakoglidis KD, Simeonidis K, Sakellari D, Stefanou G, Angelakeris M. Size-dependent mechanisms in AC magnetic 
hyperthermia response of iron-oxide nanoparticles. IEEE Trans Magn. 2012;48(4):1320–3.
 105. Gonzales-Weimuller M, Zeisberger M, Krishnan KM. Size-dependant heating rates of iron oxide nanoparticles for 
magnetic fluid hyperthermia. J Magn Magn Mater. 2009;321(13):1947–50.
 106. Purushotham S, Ramanujan RV. Modeling the performance of magnetic nanoparticles in multimodal cancer 
therapy. J Appl Phys. 2010;107(11):114701.
 107. Guardia P, Di Corato R, Lartigue L, Wilhelm C, Espinosa A, Garcia-Hernandez M, Gazeau F, Manna L, Pellegrino T. 
Water-soluble iron oxide nanocubes with high values of specific absorption rate for cancer cell hyperthermia 
treatment. ACS Nano. 2012;6(4):3080–91.
 108. Obaidat I, Issa B, Haik Y. Magnetic properties of magnetic nanoparticles for efficient hyperthermia. Nanomaterials. 
2015;5(1):63.
 109. Berkowitz AE, Lahut JA, Jacobs IS, Levinson LM, Forester DW. Spin pinning at ferrite-organic interfaces. Phys Rev 
Lett. 1975;34(10):594–7.
 110. Kalambur VS, Han B, Hammer BE, Shield TW, Bischof JC. In vitro characterization of movement, heating and visuali-
zation of magnetic nanoparticles for biomedical applications. Nanotechnology. 2005;16(8):1221–33.
 111. Chen S, Chiang C-L, Hsieh S. Simulating physiological conditions to evaluate nanoparticles for magnetic fluid 
hyperthermia (MFH) therapy applications. J Magn Magn Mater. 2010;322(2):247–52.
 112. Di Corato R, Espinosa A, Lartigue L, Tharaud M, Chat S, Pellegrino T, Ménager C, Gazeau F, Wilhelm C. Mag-
netic hyperthermia efficiency in the cellular environment for different nanoparticle designs. Biomaterials. 
2014;35(24):6400–11.
 113. Wust P, Gneveckow U, Johannsen M, Böhmer D, Henkel T, Kahmann F, Sehouli J, Felix R, Ricke J, Jordan A. Magnetic 
nanoparticles for interstitial thermotherapy-feasibility, tolerance and achieved temperatures. Int J Hyperth. 
2006;22(8):673–85.
 114. Rast L, Harrison JG. Computational modeling of electromagnetically induced heating of magnetic nanoparticle 
materials for hyperthermic cancer treatment. In: PIERS. Cambridge; 2010. p. 910–4.
 115. Candeo A, Dughiero F. Numerical FEM models for the planning of magnetic induction hyperthermia treatments 
with nanoparticles. IEEE Trans Magn. 2009;45(3):1658–61.
Page 21 of 22Suriyanto et al. BioMed Eng OnLine  (2017) 16:36 
 116. Cervadoro A, Giverso C, Pande R, Sarangi S, Preziosi L, Wosik J, Brazdeikis A, Decuzzi P. Design maps for the hyper-
thermic treatment of tumors with superparamagnetic nanoparticles. PLoS ONE. 2013;8(2):e57332.
 117. Atkinson WJ, Brezovich IA, Chakraborty DP. Usable frequencies in hyperthermia with thermal seeds. IEEE Trans 
Biomed Eng. 1984;BME-31(1):70–5.
 118. Bellizzi G, Bucci OM, Chirico G. Numerical assessment of a criterion for the optimal choice of the operative 
conditions in magnetic nanoparticle hyperthermia on a realistic model of the human head. Int J Hyperth. 
2016;32(6):688–703.
 119. Petryk AA, Misra A, Mazur CM, Petryk JD, Hoopes PJ. Magnetic nanoparticle hyperthermia cancer treatment 
efficacy dependence on cellular and tissue level particle concentration and particle heating properties; 2015. p. 
93260L-93260L-93267.
 120. Pavel M, Gradinariu G, Stancu A. Study of the optimum dose of ferromagnetic nanoparticles suitable for cancer 
therapy using MFH. IEEE Trans Magn. 2008;44(11):3205–8.
 121. Khandhar AP, Ferguson RM, Krishnan KM. Monodispersed magnetite nanoparticles optimized for magnetic fluid 
hyperthermia: implications in biological systems. J Appl Phys. 2011;109(7):07B310.
 122. Rabin Y. Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? Int J Hyperth. 
2002;18(3):194–202.
 123. Tropea BI, Lee RC. Thermal injury kinetics in electrical trauma. J Biomech Eng. 1992;114(2):241–50.
 124. Diller KR. Fundamentals of bioheat transfer. In: Moros E, editor. Physics of thermal therapy: fundamentals and clini-
cal applications. Boca Raton: CRC Press; 2012.
 125. Patterson J, Strang R. The role of blood flow in hyperthermia. Int J Radiat Oncol Biol Phys. 1979;5(2):235–41.
 126. Miaskowski A, Sawicki B. Magnetic fluid hyperthermia modeling based on phantom measurements and realistic 
breast model. IEEE Trans Biomed Eng. 2013;60(7):1806–13.
 127. Pennes HH. Analysis of tissue and arterial blood temperatures in the resting human forearm. J Appl Physiol. 
1948;1(2):93–122.
 128. Wulff W. The energy conservation equation for living tissue. IEEE Trans Biomed Eng. 1974;6(BME-21):494–5.
 129. Chen MM, Holmes KR. Microvascular contributions in tissue heat transfer. Ann of the NY Acad Sci. 
1980;335(1):137–50.
 130. Weinbaum S, Jiji LM, Lemons DE. Theory and experiment for the effect of vascular microstructure on surface tissue 
heat transfer—part I: anatomical foundation and model conceptualization. J Biomech Eng. 1984;106(4):321–30.
 131. Jiji LM, Weinbaum S, Lemons DE. Theory and experiment for the effect of vascular microstructure on surface tissue 
heat transfer—part II: model formulation and solution. J Biomech Eng. 1984;106(4):331–41.
 132. Weinbaum S, Jiji LM. A new simplified bioheat equation for the effect of blood flow on local average tissue tem-
perature. J Biomech Eng. 1985;107(2):131–9.
 133. Arkin H, Xu LX, Holmes KR. Recent developments in modeling heat transfer in blood perfused tissues. IEEE Trans 
Biomed Eng. 1994;41(2):97–107.
 134. Andrä W, d’Ambly CG, Hergt R, Hilger I, Kaiser WA. Temperature distribution as function of time around a small 
spherical heat source of local magnetic hyperthermia. J Magn Magn Mater. 1999;194(1):197–203.
 135. Sawyer CA, Habib AH, Miller K, Collier KN, Ondeck CL, McHenry ME. Modeling of temperature profile during mag-
netic thermotherapy for cancer treatment. J Appl Phys. 2009;105(7):07B320.
 136. Bagaria HG, Johnson DT. Transient solution to the bioheat equation and optimization for magnetic fluid hyper-
thermia treatment. Int J Hyperth. 2005;21(1):57–75.
 137. Pearce JA, Cook JR, Hoopes PJ, Giustini A. FEM numerical model study of heating in magnetic nanoparticles. In: 
SPIE BiOS. International Society for Optics and Photonics; 2011. p. 79010B-79010B-79019.
 138. Pavel M, Stancu A. Ferromagnetic nanoparticles dose based on tumor size in magnetic fluid hyperthermia cancer 
therapy. IEEE Trans Magn. 2009;45(11):5251–4.
 139. Pavel M, Stancu A. Study of the optimum injection sites for a multiple metastases region in cancer therapy by 
using MFH. IEEE Trans Magn. 2009;45(10):4825–8.
 140. Yue K, Yu C, Lei Q, Luo Y, Zhang X. Numerical simulation of effect of vessel bifurcation on heat transfer in the mag-
netic fluid hyperthermia. Appl Therm Eng. 2014;69(1–2):11–8.
 141. Nabil M, Decuzzi P, Zunino P. Modelling mass and heat transfer in nano-based cancer hyperthermia. R Soc Open 
Sci. 2015;2(10):150447.
 142. Chen ZP, Miller WH, Roemer RB, Cetas TC. Errors between two-and three-dimensional thermal model predictions 
of hyperthermia treatments. Int J Hyperth. 1990;6(1):175–91.
 143. Craciun V, Calugaru G, Badescu V. Accelerated simulation of heat transfer in magnetic fluid hyperthermia. Czecho-
slov J Phys. 2002;52(5):725–8.
 144. Reis RF, Loureiro FDS, Lobosco M. 3D numerical simulations on GPUs of hyperthermia with nanoparticles by a 
nonlinear bioheat model. J Comput Appl Math. 2016;295:35–47.
 145. Mital M, Tafreshi HV. A methodology for determining optimal thermal damage in magnetic nanoparticle hyper-
thermia cancer treatment. Int J Numer Methods Biomed Eng. 2012;28(2):205–13.
 146. Salloum M, Ma R, Zhu L. Enhancement in treatment planning for magnetic nanoparticle hyperthermia: optimiza-
tion of the heat absorption pattern. Int J Hyperth. 2009;25(4):309–21.
 147. Carnochan P, Dickinson RJ, Joiner MC. The practical use of thermocouples for temperature measurement in clini-
cal hyperthermia. Int J Hyperth. 1986;2(1):1–19.
 148. Hynynen K, Martin CJ, Watmough DJ, Mallard JR. Errors in temperature measurement by thermocouple probes 
during ultrasound induced hyperthermia. Br J Radiol. 1983;56(672):969–70.
 149. Carter DL, MacFall JR, Clegg ST, Wan X, Prescott DM, Charles HC, Samulski TV. Magnetic resonance thermometry 
during hyperthermia for human high-grade sarcoma. Int J Radiat Oncol Biol Phys. 1998;40(4):815–22.
 150. Guimarães AP. Principles of nanomagnetism. Berlin: Springer Science & Business Media; 2009.
 151. Krishnan KM. Biomedical nanomagnetics: a spin through possibilities in imaging, diagnostics, and therapy. IEEE 
Trans Magn. 2010;46(7):2523–58.
Page 22 of 22Suriyanto et al. BioMed Eng OnLine  (2017) 16:36 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 152. Karimi Z, Karimi L, Shokrollahi H. Nano-magnetic particles used in biomedicine: core and coating materials. Mater 
Sci Eng C. 2013;33(5):2465–75.
 153. Gubin SP. Magnetic nanoparticles. New York: Wiley; 2009.
 154. Shirk B, Buessem W. Theoretical and experimental aspects of coercivity versus particle size for barium ferrite. IEEE 
Trans Magn. 1971;7(3):659–63.
 155. Klemmer T, Hoydick D, Okumura H, Zhang B, Soffa WA. Magnetic hardening and coercivity mechanisms in L10 
ordered FePd ferromagnets. Scr Metall et Mater. 1995;33(10–11):1793–805.
 156. Fortin J-P, Wilhelm C, Servais J, Ménager C, Bacri J-C, Gazeau F. Size-sorted anionic iron oxide nanomagnets as col-
loidal mediators for magnetic hyperthermia. J Am Chem Soc. 2007;129(9):2628–35.
 157. Inomata K, Sawa T, Hashimoto S. Effect of large boron additions to magnetically hard Fe–Pt alloys. J Appl Phys. 
1988;64(5):2537–40.
 158. Vassiliou JK, Mehrotra V, Russell MW, Giannelis EP, McMichael RD, Shull RD, Ziolo RF. Magnetic and optical proper-
ties of γ-Fe2O3 nanocrystals. J Appl Phys. 1993;73(10):5109–16.
 159. Sato T, Iijima T, Seki M, Inagaki N. Magnetic properties of ultrafine ferrite particles. J Magn Magn Mater. 
1987;65(2):252–6.
 160. Kambale RC, Shaikh PA, Kamble SS, Kolekar YD. Effect of cobalt substitution on structural, magnetic and electric 
properties of nickel ferrite. J Alloy Compd. 2009;478(1–2):599–603.
